Author Title [ Type(Desc)] Year
Filters: Author is Aplenc, Richard  [Clear All Filters]
Journal Article
Freedman JL, Desai AV, L Bailey C, Aplenc R, Burnworth B, Zehentner BK, Teachey DT, Wertheim G. Atypical chronic myeloid leukemia in two pediatric patients. Pediatr Blood Cancer. 2015.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2014;371(16):1507-1517.
Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang Y-S, Arnold S, Seif AE, Miller TP, et al. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015.
Tarlock K, Alonzo TA, Gerbing R, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis A, et al. Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. Clin Cancer Res. 2015.
Cahen VC, Li Y, Getz KD, Elgarten CW, DiNofia AM, Wilkes JJ, Winestone LE, Huang Y-SV, Miller TP, M Gramatges M, et al. Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatr Blood Cancer. 2020:e28315.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Seif AE, Li Y, Monos DS, Heidemann SC, Aplenc R, Barrett DM, Casper JT, Freedman JL, Grupp SA, Margolis DA, et al. Partially CD3-depleted unrelated and haploidentical donor PSCT has favorable GVHD and survival rates in pediatric hematologic malignancy. Biol Blood Marrow Transplant. 2019.
Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy. Curr Opin Pediatr. 2019.
Bona K, Li Y, Winestone LE, Getz KD, Huang Y-S, Fisher BT, Desai AV, Richardson T, Hall M, Naranjo A, et al. Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma. J Natl Cancer Inst. 2020.
Pan Y, Kadash-Edmondson KE, Wang R, Phillips J, Liu S, Ribas A, Aplenc R, Witte ON, Xing Y. RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets. Trends Pharmacol Sci. 2021;42(4):268-282.